SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-024590
Filing Date
2021-10-05
Accepted
2021-10-05 10:00:19
Documents
13
Period of Report
2021-10-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36762
2 ex99-1.htm EX-99.1 12039
  Complete submission text file 0001493152-21-024590.txt   224458

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mymd-20211005.xsd EX-101.SCH 3012
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mymd-20211005_lab.xml EX-101.LAB 34239
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mymd-20211005_pre.xml EX-101.PRE 22350
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3610
Mailing Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 623 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 211305376
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences